An Alzheimer’s drug could prevent dementia before symptoms show, with research suggesting it could clear toxic brain plaques in just three months.
Trontinemab, a medicine given as a monthly infusion, will be offered to about 1,600 people with no memory problems who are at high risk of the disease to see whether it can stave off symptoms.
Scientists said the landmark trial could be a “game changer”, raising the prospect of “statins for the brain” being routinely offered to people in mid-life.
The phase III trial – the final pre-approval testing stage for a new treatment – will use blood tests to identify those most likely to benefit from taking part.
No comments:
Post a Comment